Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,086 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,118
- Phase 1823
- Phase 1/Phase 2484
- Phase 3349
- Phase 4126
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma333
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease142
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- Mayo Clinic61
- City of Hope Medical Center60
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama146
- Arizona123
- Florida111
- Massachusetts101
- New York98
- Ohio71
- Minnesota68
Recruiting studies5,086 total
- NCT04627753RecruitingPhase 2
Lenalidomide plus rituximab to prevent brain lymphoma return
This trial studies whether lenalidomide and rituximab can help keep primary CNS lymphoma from coming back after initial chemotherapy. It may be an option if you cannot do a transplant and you can take pills.
SeoulAges 19 years+ - NCT04138927Enrolling by invitationPhase 3
Long-term fostamatinib use for warm autoimmune anemia
This study checks the benefits and safety of continuing fostamatinib over the long term for people with warm autoimmune hemolytic anemia. It may help by reducing the body’s immune attack on red blood cells, and it’s designed for people who already finished a prior part of the study.
Los Angeles, CaliforniaAges 18–100 - NCT03849443RecruitingEarly Phase 1
Testing tranexamic acid to reduce bleeding after spine fusion
This trial studies whether a single dose or multiple doses of tranexamic acid (TXA) can reduce the chance you need a blood transfusion after spine fusion surgery. It also compares two different ways TXA may be given (by mouth and through a vein) to see which approach works best and is safe.
Chicago, IllinoisAges 18 years+ - NCT03919305Recruiting
Study of blood clots in brain veins
This study follows people who have a blood clot in the brain’s venous drainage system. It aims to better understand this condition and may help improve how it is recognized and managed.
BeijingAges Any age - NCT05755087RecruitingPhase 1
Tegavivint for relapsed or hard-to-treat lymphoma patients
This Phase 1 trial tests tegavivint, a new investigational medicine, for certain types of aggressive B-cell lymphoma that have come back or did not respond to prior treatment. It may help shrink the lymphoma and learn how safe and effective the drug is in this setting.
Columbus, OhioAges 18 years+ - NCT04157569Recruiting
Study blood DNA markers after chemotherapy in older acute leukemia
This trial checks a blood test called “ctDNA” (tiny pieces of leukemia DNA in blood) after chemotherapy. It may help doctors understand how well treatment is working in older adults with acute leukemia.
BeijingAges 60–100 - NCT00902447Recruiting
Blood and tissue collection for future research studies
This trial is a tissue and blood bank that collects samples for future research. You may be asked to give blood and/or tissue again later, but it is meant to be done without interfering with your care.
Manhasset, New YorkAges 18–100 - NCT03980769RecruitingPhase 2
Stem cell transplant trial for non-cancer blood disorders
This Phase 2 study tests a specific chemotherapy combination (treosulfan, fludarabine, and thiotepa) before an unrelated or matched donor stem cell transplant. It may help people with certain non-cancer blood and immune disorders by trying to reset the immune system using donor stem cells.
Seattle, WashingtonAges Up to 50 years - NCT01189786Recruiting
Stem cell transplant add-on that removes some immune cells
This trial tests a lab-made cell treatment added around an allogeneic stem cell transplant (donor transplant). It tries to improve transplant safety and outcomes by removing certain immune cells from the donor stem cells.
Houston, TexasAges Up to 70 years - NCT05605574Recruiting
Advance care planning talks for young transplant patients
This study tests a structured set of conversations about future medical care (advance care planning) for adolescents and young adults who are preparing for a stem cell transplant. It also involves a caregiver (and the care team) to help ensure the discussions are understood, documented, and completed at the right times.
Baltimore, MarylandAges 18–120 - NCT03571568RecruitingPhase 1/Phase 2
Study of BI-1206 plus rituximab, with or without acalabrutinib
This early-phase study tests BI-1206 combined with rituximab, and possibly adds acalabrutinib, in people with certain slow-growing B-cell lymphomas that have come back or did not respond to prior treatment. The goal is to see whether this treatment approach shrinks lymphoma safely and effectively.
Atlanta, GeorgiaAges 18 years+ - NCT03000244Recruiting
Long-term follow-up after stem cell or gene therapy
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
Bethesda, MarylandAges 4–120 - NCT03357172Recruiting
Study immune changes after a stem cell transplant
This study looks at how the immune system changes after an allogeneic stem cell transplant (using a donor’s stem cells). It may help researchers understand what controls immune recovery and transplant-related complications.
Vandœuvre-lès-NancyAges 18 years+ - NCT02881970RecruitingPhase 1/Phase 2
Cord blood stem cell treatment for newborn brain injury
This early-phase study tests whether using a baby’s own cord blood stem cells is safe and feasible for newborns with brain injury from lack of oxygen around birth. It may help researchers find new ways to treat hypoxic-ischemic encephalopathy (brain injury due to oxygen deprivation) in addition to standard care like cooling.
MarseilleAges 1 day–3 days - NCT03356054RecruitingPhase 1/Phase 2
Test drug for CD30-positive lymphoma after first treatment fails
This early-phase study tests a lymphoma treatment in adults whose diffuse large B-cell lymphoma (DLBCL) is “CD30-positive” and who didn’t respond well to first-line chemotherapy (like R-CHOP) or had an early relapse. It aims to see if the treatment can shrink the lymphoma and is safe enough to move forward.
RotterdamAges 18 years+ - NCT05436561RecruitingPhase 2
Test a reduced transplant plan for older leukemia patients
This Phase 2 trial studies a “reduced-intensity” transplant plan for people age 55–65 who have certain blood cancers and a suitable donor. It may help older patients get the benefits of a transplant with less treatment burden, but it excludes people with serious organ problems or active infections.
Shanghai, Shanghai MunicipalityAges 55–65 - NCT03013998RecruitingPhase 1/Phase 2
Biomarker-guided treatment study for older adults with AML
This trial studies whether choosing treatment based on lab test “biomarkers” (specific genetic or blood markers) can help people with acute myeloid leukemia (AML). It focuses on adults who are not good candidates for the most intensive chemotherapy, and it uses different sub-studies for different AML types.
Phoenix, ArizonaAges 18 years+ - NCT02797717Recruiting
Treatment study for classical Hodgkin lymphoma in young people
This trial looks at a treatment approach for children and adolescents with classical Hodgkin lymphoma. It may help by testing how well the treatment controls the cancer and is tolerable in young patients.
Petah TikvaAges 1 month–18 years - NCT05524298Recruiting
Quality of life study in older adults with low-grade lymphoma
This study looks at quality of life in people age 70 and older with slow-growing (low-grade) B-cell non-Hodgkin lymphoma who haven’t been treated yet. It requires a geriatric (aging-focused) check before starting care, to see what helps older patients feel better during treatment.
Alessandria, AlessandriaAges 70 years+ - NCT05545930Recruiting
Testing a sponge device to help blood recovery after heart surgery
This study looks at a new surgical sponge and blood-recovery device during major heart or lung operations. It aims to improve how efficiently blood is recovered and returned, which may help during surgery.
Cleveland, OhioAges 18–89 - NCT02312830Enrolling by invitation
Study of long-term transplant survivors at one Belgian hospital
This study invites adults who had a donor (allogeneic) transplant at KU Leuven long ago to share health information during a scheduled checkup. It may help researchers better understand long-term outcomes and support needs after transplant.
Ages 18–100 - NCT01163578Recruiting
Using test results to improve outcomes after organ or marrow transplant
This study looks at “biomarkers,” which are measurable lab signals, in people who have had an organ or bone marrow transplant. The goal is to use these test results to better predict and improve transplant outcomes.
Pittsburgh, PennsylvaniaAges Any age - NCT03031249Enrolling by invitationPhase 1/Phase 2
Testing ATO plus ATRA for NPM1-mutated AML after remission
This trial studies whether a combination medicine (ATO plus ATRA) is safe and works better in people with a specific type of AML (acute myeloid leukemia) caused by an NPM1 mutation. You would join only after your leukemia has reached remission, meaning the active leukemia has cleared after initial treatment.
Tianjin, Tianjin MunicipalityAges 14–55 - NCT05864170RecruitingEarly Phase 1
Tested injection for severe transfusion-dependent thalassemia
This early-stage study tests the safety and possible benefits of an injection called HGI-001 for people with severe transfusion-dependent beta thalassemia. It may help by preparing you for stem cell transplant, but you must meet several health and lab criteria and be able to return often for follow-up tests.
Shenzhen, GuangdongAges 18–35
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,086 recruiting hematology studies from the U.S. registry right now, out of 7,699 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.